Relay Therapeutics
RLAY
199 hedge funds and large institutions have $676M invested in Relay Therapeutics in 2024 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 87 increasing their positions, 36 reducing their positions, and 37 closing their positions.
441% more call options, than puts
Call options by funds: $606K | Put options by funds: $112K
142% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 36
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
16% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 37
2% more funds holding
Funds holding: 195 → 199 (+4)
2.64% less ownership
Funds ownership: 100.59% → 97.95% (-2.6%)
42% less capital invested
Capital invested by funds: $1.16B → $676M (-$481M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$24.5M |
| 2 |
BlackRock
New York
|
+$16M |
| 3 |
Millennium Management
New York
|
+$8.21M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.62M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$5.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$24.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$12.1M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$10.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.7M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.1M |
RLAY Hedge Fund Activity: Q4 2024 in Review
199 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q4 2024, worth a combined $676M — down 42% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new RLAY positions and 37 closed out — a net gain of 6 holders — while 87 added to existing stakes and 36 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $24.5M. The largest seller was Braidwell, exiting entirely with an estimated $24.8M sold.
- 199 institutional investors held Relay Therapeutics (RLAY) as of Q4 2024, up from 195 in Q3 2024.
- Funds reported $676M of Relay Therapeutics stock for Q4 2024, down 42% quarter-over-quarter.
- 43 funds opened new Relay Therapeutics positions in Q4 2024 and 37 closed out, a net change of +6 holders.
- The largest Relay Therapeutics buyer in Q4 2024 was Tang Capital Management, an estimated $24.5M added.
- The largest Relay Therapeutics seller in Q4 2024 was Braidwell, an estimated $24.8M sold.
Based on aggregated 13F filings for Q4 2024.